These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Therapeutic potential of vasopressin receptor antagonists. Ali F; Guglin M; Vaitkevicius P; Ghali JK Drugs; 2007; 67(6):847-58. PubMed ID: 17428103 [TBL] [Abstract][Full Text] [Related]
6. Tolvaptan for the treatment of hyponatremia and congestive heart failure. Ferrer E Drugs Today (Barc); 2010 Mar; 46(3):163-71. PubMed ID: 20467590 [TBL] [Abstract][Full Text] [Related]
7. Diagnosis and management of hyponatraemia in the older patient. Woodward M; Gonski P; Grossmann M; Obeid J; Scholes R; Topliss DJ Intern Med J; 2018 Jan; 48 Suppl 1():5-12. PubMed ID: 29318728 [TBL] [Abstract][Full Text] [Related]
8. Vasopressin receptor antagonist in the treatment of the syndrome of inappropriate antidiuretic hormone in general hospital practice. Rajendran R; Grossman AB; Kar P Endocr J; 2012; 59(10):903-9. PubMed ID: 22785335 [TBL] [Abstract][Full Text] [Related]
9. Treatment of hypervolemic or euvolemic hyponatremia associated with heart failure, cirrhosis, or the syndrome of inappropriate antidiuretic hormone with tolvaptan: a clinical review. Nemerovski C; Hutchinson DJ Clin Ther; 2010 Jun; 32(6):1015-32. PubMed ID: 20637957 [TBL] [Abstract][Full Text] [Related]
11. Tolvaptan (Samsca) for hyponatremia. Med Lett Drugs Ther; 2009 Nov; 51(1326):95-6. PubMed ID: 20224525 [No Abstract] [Full Text] [Related]
12. Therapeutic potential of vasopressin-receptor antagonists in heart failure. Izumi Y; Miura K; Iwao H J Pharmacol Sci; 2014; 124(1):1-6. PubMed ID: 24401675 [TBL] [Abstract][Full Text] [Related]
13. Tolvaptan, an orally active vasopressin V(2)-receptor antagonist - pharmacology and clinical trials. Miyazaki T; Fujiki H; Yamamura Y; Nakamura S; Mori T Cardiovasc Drug Rev; 2007; 25(1):1-13. PubMed ID: 17445084 [TBL] [Abstract][Full Text] [Related]
14. Vasopressin and vasopressin antagonists in heart failure and hyponatremia. Farmakis D; Filippatos G; Kremastinos DT; Gheorghiade M Curr Heart Fail Rep; 2008 Jun; 5(2):91-6. PubMed ID: 18765079 [TBL] [Abstract][Full Text] [Related]
15. Clinical review: the use of vaptans in clinical endocrinology. Peri A J Clin Endocrinol Metab; 2013 Apr; 98(4):1321-32. PubMed ID: 23401044 [TBL] [Abstract][Full Text] [Related]
16. AVP receptor antagonists as aquaretics: review and assessment of clinical data. Verbalis JG Cleve Clin J Med; 2006 Sep; 73 Suppl 3():S24-33. PubMed ID: 16970150 [TBL] [Abstract][Full Text] [Related]
17. Tolvaptan use in cancer patients with hyponatremia due to the syndrome of inappropriate antidiuretic hormone: a post hoc analysis of the SALT-1 and SALT-2 trials. Gralla RJ; Ahmad F; Blais JD; Chiodo J; Zhou W; Glaser LA; Czerwiec FS Cancer Med; 2017 Apr; 6(4):723-729. PubMed ID: 28251822 [TBL] [Abstract][Full Text] [Related]
18. Tolvaptan in hospitalized cancer patients with hyponatremia: a double-blind, randomized, placebo-controlled clinical trial on efficacy and safety. Salahudeen AK; Ali N; George M; Lahoti A; Palla S Cancer; 2014 Mar; 120(5):744-51. PubMed ID: 24895288 [TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of tolvaptan for the treatment of hyponatraemia secondary to syndrome of inappropriate antidiuretic hormone secretion in Sweden. Jamookeeah C; Robinson P; O'Reilly K; Lundberg J; Gisby M; Ländin M; Skov J; Trueman D BMC Endocr Disord; 2016 May; 16(1):22. PubMed ID: 27184496 [TBL] [Abstract][Full Text] [Related]